Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Completed
Keryx Biopharmaceuticals
2010-01-01
The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a
dietary phosphate binder in controlling and managing serum phosphorus levels in patients with
end-stage renal disease (ESRD).
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Completed
Collaborative Study Group (CSG)
Phase 2
2008-03-01
This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a
treatment for hyperphosphatemia in patients with End-Stage Renal Disease.
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Completed
Keryx Biopharmaceuticals
Phase 2
2008-03-01
This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a
treatment for hyperphosphatemia in patients with End-Stage Renal Disease.
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Completed
Keryx Biopharmaceuticals
2010-01-01
The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a
dietary phosphate binder in controlling and managing serum phosphorus levels in patients with
end-stage renal disease (ESRD).
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Completed
Collaborative Study Group (CSG)
Phase 3
2010-05-01
This is a research study for people with high blood phosphorus levels who are on dialysis.
This medical condition can cause weakening of the bones and damage other organs. This can
lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat,
and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid
of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often
patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood
phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric
citrate) is safe and effective as a phosphate binder.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
